# Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)

Source: https://onco.cc/trials/nct03801525/  
OnCo record `nct03801525` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Umbralisib and Venetoclax in Chronic lymphocytic leukaemia, run by TG Therapeutics, Inc., recorded as terminated on the registry.

## Summary

Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) is a phase 2/3 interventional study registered as NCT03801525 by TG Therapeutics, Inc., with 277 participants recorded, started 2019-05-16 and due to reach its primary completion in 2022-12-20. Interventions recorded: Ublituximab, Umbralisib, Venetoclax. Conditions recorded: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.

Linked to the drug Umbralisib because the registry names it among its interventions and Chronic lymphocytic leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03801525
- Phase: 2/3
- Setting: Phase 2/3 Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects With Chronic Lymphocytic Leukemia (CLL)
- Sponsor: TG Therapeutics, Inc.
- Enrolled: 277

## Sources

- ClinicalTrials.gov NCT03801525: https://clinicaltrials.gov/study/NCT03801525

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Umbralisib](https://onco.cc/drugs/umbralisib/), [Venetoclax](https://onco.cc/drugs/venetoclax/)

---
JSON: https://onco.cc/api/v1/entities/nct03801525.json